



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

Mail Stop 3030

May 31, 2016

Via E-mail

Lindsay A. Rosenwald, M.D.  
Chief Executive Officer  
CB Pharma Acquisition Corp.  
2 Gansevoort Street, 9th Floor  
New York, New York 10014

**Re: CB Pharma Acquisition Corp.  
Preliminary Proxy Statement on Schedule 14A  
Filed May 20, 2016  
File No. 001-36757**

Dear Dr. Rosenwald:

We have completed our limited review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Russell Mancuso

Russell Mancuso  
Branch Chief  
Office of Electronics and Machinery

cc: Jeffrey M. Gallant  
Graubard Miller